Paragraph IV, 30-month stays and 180-day exclusivity: why US generic timing does not transfer to Europe

Why the confusion arises

The largest patent-expiry databases, most trade press and most investor commentary are American, and they describe a system built by one statute, the Hatch-Waxman Act of 1984, that links the regulator to the patent system. Europe never built that link. A reader who takes a US timeline and applies it to the EU gets the dates wrong and the mechanism wrong. The table sets the two side by side; the sections explain the differences that cost money.

	United States	European Union (and the UK, in most respects)
Patents listed with the regulator	Yes: the Orange Book lists patents the originator says cover the product	No list; the regulator does not consider patents
Generic application	ANDA, with a certification for each listed patent (Paragraph I to IV)	Generic application under Article 10, no patent certification
Patent challenge trigger	Paragraph IV certification: a notice that the generic will contest the patent	None; a generic simply applies, and may sue to revoke or wait to be sued
Automatic stay of approval	30 months if the originator sues within 45 days	None; approval proceeds regardless of litigation
First-filer reward	180 days of generic exclusivity for the first Paragraph IV filer	None; every approved generic may launch at once
Regulatory exclusivity for a new compound	5 years (NCE), Paragraph IV filing allowed at 4	8 years of data protection, 2 (+1) of market protection, from the first EU authorisation
Biologics	12 years from approval (4 before a biosimilar application)	The same 8+2+1 as any product
Orphan	7 years	10 years (tiered under the reform)
Paediatric reward	6 months added to patents and exclusivities	6 months added to the SPC (2 years of orphan exclusivity instead)
Patent term restoration	PTE: up to 5 years, one patent, 14-year cap from approval	SPC: up to 5 years, one certificate per product per state, 15-year cap from first EU authorisation
Research exemption	Broad safe harbour (271(e)(1))	Bolar exemption, narrower; widened by the pharmaceutical package
Launch before judgment	“At-risk launch” after the stay or without one	“Launch at risk”, met by a preliminary injunction application
Where it is fought	One federal district court, then the Federal Circuit	Country by country, or at the Unified Patent Court for its states

No linkage: the regulator does not read patents

In the EU, marketing authorisation can be refused or withheld only on the grounds in the Directive, and patent status is not one of them. A generic is authorised at the end of the procedure whether or not a patent is asserted; the originator’s remedy is in court. There is nothing to certify, no notice to serve and no stay to trigger. The practical consequence is that the European dates on which a generic could launch are the regulatory dates and the patent and SPC dates, read together, with the fight, if any, happening in parallel rather than as a gate.

No 180 days: everyone launches together

The US rewards the first challenger with a six-month head start, which is why US generic entry is often a one-company event at a high price. Europe has no equivalent: every generic with an authorisation may launch on the day the last exclusivity ends, and in practice five to fifteen do, in the UK and Germany within days. Prices therefore fall faster and further in Europe at the start, and there is no window in which one generic enjoys the brand’s price.

Different clocks, different start dates

US exclusivity runs from US approval; EU data protection runs from the first EU authorisation, which is often a year or more later than the US approval for the same product. The PTE and the SPC are calculated differently and capped differently (fourteen years from US approval versus fifteen years from first EU authorisation, with a five-year maximum in both), so the restored patent expiry in the US and the SPC expiry in Germany are unrelated numbers that happen to be a few years apart. An Orange Book patent, moreover, may have no European counterpart, or a European counterpart that was never validated in the country you care about.

Litigation: injunctions instead of stays

Where the US system pauses approval for thirty months to let a court decide, Europe lets the generic launch and lets the originator ask a court to stop it. The decision whether to hold the ring is made quickly, on an incomplete record, under tests that differ between London, Düsseldorf, The Hague and the UPC, and it decides supply for a year or more. The European equivalent of “will the generic be approved in time” is “will the generic be injuncted”, which is a question about secondary patents, timing and jurisdiction rather than about the regulator.

Reading US sources for European decisions

• A US “patent expiry” date for a product says nothing about the European SPC date; find the European first-authorisation date and compute.
• “First-to-file” and “180-day exclusivity” have no European effect; the European entry is multi-source from day one.
• A “30-month stay” expiring is a US event; European approvals were never paused.
• “Launched at risk” means something different: in Europe it means an injunction application is coming.
• Orange Book patents are the originator’s own selection and omit process patents; European secondary patents must be found in the national registers.

MPA Search records the European first-authorisation dates, patents, SPCs and licences from which European entry dates are actually derived; the PTE explainer covers the arithmetic in both systems.